Why is cortisone (prednisone) prescribed for liver disease?

Why Corticosteroids Are Prescribed for Liver Disease

Corticosteroids, particularly prednisone or prednisolone, are prescribed for specific types of liver disease—primarily autoimmune hepatitis, severe alcoholic hepatitis, drug-induced autoimmune-like hepatitis, and immune checkpoint inhibitor-induced hepatitis—where they suppress the immune-mediated inflammation that drives liver injury and prevents progression to cirrhosis and liver failure.

Autoimmune Hepatitis (AIH)

Prednisone is the cornerstone of treatment for autoimmune hepatitis and achieves biochemical remission in 80% of patients within 6 months. 1, 2

Treatment Indications

• Mandatory treatment when serum aminotransferase levels exceed 10-fold the upper limit of normal 2, 3
• Mandatory treatment when aminotransferases exceed 5-fold the upper limit with γ-globulin levels at least twice the upper limit of normal 2, 3
• Any patient with moderate-to-severe autoimmune hepatitis should receive prednisone therapy 2

Standard Treatment Regimens

• The optimal approach is combination therapy with prednisone plus azathioprine, which reduces corticosteroid-related side effects from 44% to 10% compared to prednisone monotherapy 2, 3, 4
• Initial dosing: prednisone 30 mg/day + azathioprine 50 mg/day for week 1, then gradual taper to maintenance doses 2
• Prednisone monotherapy (40-60 mg daily initially) is reserved for patients who cannot tolerate azathioprine or require treatment for less than 6 months 1

Acute Severe Autoimmune Hepatitis

• Patients with acute severe presentation require immediate high-dose intravenous corticosteroids (≥1 mg/kg daily) 2, 3
• If no improvement within 7 days, evaluate for liver transplantation 3

Mechanism and Response

• Prednisone suppresses cytokine gene expression and inhibits differentiation and proliferation of activated lymphocytes 5
• Serum aminotransferase levels should improve within 2 weeks of starting therapy, which is the most important predictor of outcome 2, 3
• Treatment must continue for at least 2 years and for at least 12 months after normalization of liver enzymes 2

Severe Alcoholic Hepatitis

Prednisolone 40 mg daily is indicated for severe alcoholic hepatitis with Maddrey Discriminant Function ≥32 or MELD score >20, where it reduces short-term mortality. 1

Treatment Protocol

• Screen for contraindications: uncontrolled infection, acute kidney injury with creatinine >2.5 mg/dL, uncontrolled GI bleeding, multiorgan failure 1
• Assess response using Lille score at day 7 1
• If Lille score <0.45, continue prednisolone for 28 days total 1
• Infections are common (12-26% at admission, up to 50% during treatment), requiring vigilant monitoring 1

Drug-Induced Autoimmune-Like Hepatitis (DI-AIH)

Patients with drug-induced autoimmune hepatitis show excellent response to corticosteroids with rapid and long-lasting effects. 6

• All five observational studies on DI-AIH demonstrated good therapeutic response 6
• Patients typically achieve remission without evidence of relapse after corticosteroid discontinuation 6

Immune Checkpoint Inhibitor (ICI) Hepatitis

Systemic glucocorticoids represent the primary treatment for ICI hepatitis that does not resolve spontaneously. 1

Graded Treatment Approach

• Grade 2 (AST/ALT >3-5× ULN): Hold ICI; if symptoms present or no resolution after 1-2 weeks, start prednisone 0.5-1.0 mg/kg/day 1
• Grade 3 (AST/ALT >5-20× ULN): Discontinue ICI; start methylprednisolone 1-2 mg/kg with 4-6 week taper 1
• Grade 4 (AST/ALT >20× ULN or hepatic decompensation): Hospitalize; permanently discontinue ICI; start methylprednisolone 2 mg/kg/day 1
• 33-50% of ICI hepatitis cases improve spontaneously, but 72% of treated patients respond to steroids 6

Important Caveats and Contraindications

When NOT to Use Corticosteroids

• Drug-induced fulminant acute liver failure: Steroid therapy was not associated with improved overall survival 6
• Active uncontrolled infections 1
• Hepatitis B or C coinfection requires careful consideration; corticosteroids can increase HCV viremia and fibrosis progression 1

Pharmacokinetic Considerations

• Prednisone is converted to active prednisolone in the liver 5, 7
• Patients with active liver disease and hypoalbuminemia have decreased protein binding and delayed clearance, resulting in higher levels of biologically active drug 7, 8
• Despite impaired conversion, advanced cirrhosis does not sufficiently suppress prednisone-to-prednisolone conversion to warrant preferential use of prednisolone 3

Side Effect Management

• 80% of patients develop cosmetic changes after 2 years of therapy 3
• Severe complications (osteoporosis, diabetes, cataracts) typically develop after 18 months at doses >10 mg daily 3
• All patients must receive calcium and vitamin D supplementation from treatment initiation 2
• Monitor bone mineral density with DEXA scanning at 1-2 year intervals 2, 3

Alternative for Select Patients

• Budesonide 9 mg/day plus azathioprine may be used in treatment-naive, non-cirrhotic patients with early-stage autoimmune hepatitis who face high risk of steroid side effects 2, 5
• Budesonide should not be used in cirrhosis due to portal hypertensive shunts preventing adequate hepatic delivery 1